Sick enough: the silent struggles of sub-clinical illness in modern medicine
To live in the grey zone of sub-clinical pathology is to be unwell enough to hurt, but not enough to be heard.
Latest
In the Company of Shadows: Love, Labour, and the Long Way Through
First-generation medical students carry two textbooks - one devoted to anatomy, the other towards cultivating resilience.
Electricity Designed for the Future: EDF power solutions’ Tristan Grimbert on Competing in North America’s Toughest Energy Market
"We call it the post-COVID storm. Inflation, tariffs, interconnection delays - it’s never been harder to deliver fixed-price projects with long lifecycles,” Tristan Grimbert explains how EDF power solutions is navigating today’s volatile energy economics.
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
✨ Onyx Summary Guardant Health and Quest Diagnostics announced a multi-year strategic collaboration to make Guardant’s FDA-approved Shield™ blood test for colorectal cancer screening available through Quest’s vast provider network, patient service centers, and phlebotomy teams nationwide starting in early 2026. By pairing Shield’s simplicity with Quest’s
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
✨ Onyx Summary Kyverna Therapeutics reported updated Phase 1 data from investigator-initiated trials of its CD19 CAR T-cell therapy, KYV-101, in progressive multiple sclerosis, showing favorable safety, CNS penetration, and early signs of disease stabilization or improvement. The data, presented by Stanford and UCSF at the 2025 ECTRIMS Congress, reinforce KYV-101’
PowerTrack and Stem, Inc.’s Push for Renewable Confidence
"The CEO’s role isn’t operational - it’s to set the long-term vision and take the risk buffer so others can take the micro bets that are needed to help grow the business,” Arun Narayanan explains why long-term thinking is essential to scaling sustainable energy.
Advanced Clinical Announces Leadership Transition
✨ Onyx Summary Advanced Clinical announced that CEO Julie Ross has departed to pursue a new opportunity, with Founder and Owner Leo Sheridan assuming the role of Chief Executive Officer. Supported by a seasoned leadership team, the transition underscores the company’s continued focus on global growth, operational excellence, and delivering
Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors
✨ Onyx Summary Cellares appointed Chris McDonald, former SVP and Global Head of Technical Operations at Kite (a Gilead Company), to its Advisory Board. McDonald brings more than 35 years of experience scaling global biomanufacturing operations at Kite, Amgen, Novartis, and AstraZeneca, expertise that will support Cellares’ international expansion of its
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
✨ Onyx Summary Lexicon Pharmaceuticals announced that the FDA will require additional time to review newly submitted clinical data supporting the potential resubmission of its New Drug Application for Zynquista® (sotagliflozin) as an adjunct therapy for adults with type 1 diabetes, with feedback now expected in Q4 2025. The update follows
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
✨ Onyx Summary Adverum Biotechnologies announced it will complete screening by September 30 for ARTEMIS, its first pivotal Phase 3 trial of Ixo-vec in wet age-related macular degeneration (AMD), with full enrollment of at least 284 patients expected in 4Q 2025 and data readout in 1Q 2027. The ARTEMIS study marks
Capital With Conviction: How Khosla Ventures Walks With Founders for 10x Impact
"We’re hunting for the twelve entrepreneurs that will save the world - the 12 instigators,” Khosla Ventures' Rajesh Swaminathan highlights the firm’s disciplined focus on breakthrough founders and bold science.
MassBio and Google empower biotech workers with AI for Drug Discovery Training
✨ Onyx Summary MassBio and Google co-hosted the 2025 AI for Drug Discovery Training in Cambridge, bringing together more than 60 life sciences professionals from start-ups, academia, and pharma for hands-on sessions with Google’s Gemini and Vertex AI platforms. By equipping the Massachusetts biotech community with AI-driven skills, the program
Not Just Net Zero: Why B Corps Must Lead the Charge on Equity and Emissions
"The beating heart and soul of this movement are smaller- and medium-sized enterprises,” Kylie Nealis explains how B Lab™ is raising the bar for business standards in climate justice.
How AI, Carbon Markets, and Co-Ops Are Changing the Economics of Farming
"Changing the mindset from ‘more fertilizer equals more grain’ to ‘resilient soils equals profitability’ takes proof,” Arva Intelligence's Jay McEntire underlines how farmers themselves are the real heroes of regenerative agriculture.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
✨ Onyx Summary Geron Corporation granted inducement equity awards to 16 new hires totaling 966,000 shares—644,000 stock options at a $1.27 exercise price and 322,000 RSUs—under Nasdaq Listing Rule 5635(c)(4), with grants dated September 17, 2025 and four-year vesting schedules. The move aligns
Launching the Palmetto Beacon Venture Fellowship: Building a stronger investor ecosystem
✨ Onyx Summary MassBio, SCbio, Venture Carolina, VentureSouth, and the South Carolina Department of Commerce launched the Palmetto Beacon Venture Fellowship, a program designed to educate and empower the next generation of biotech investors through immersive sessions in Charleston, John’s Island, and Boston. By bridging ecosystems from the Southeast to